Evidence-based medicine (EBM) is the integration of individual clinical expertise with the best available research evidence from systematic research and the patient's values and expectations. A hierarchy of evidence can be used to assess the strength upon which clinical decisions are made. The efficient approach to finding the best evidence is to identify systematic reviews or evidence-based clinical practice guidelines. Respiratory therapies that evidence supports include noninvasive ventilation for appropriately selected patients, lung-protective ventilation, and ventilator discontinuation protocols. Evidence does not support use of weaning parameters, albuterol for ARDS, and high frequency oscillatory ventilation for adults. Therapy with equivocal evidence includes airway clearance, selection of an aerosol delivery device, and PEEP for ARDS. Although all tenets of EBM are not universally accepted, the principles of EBM nonetheless provide a valuable approach to respiratory care practice. Key Words: clinical practice guideline; evidence-base medicine; meta-analysis; systematic review.
Introduction
Early in my career, the proceedings of the Conference on the Scientific Basis of Respiratory Therapy, commonly called the Sugarloaf Conference, were published. 1 These proceedings came as a shock to me and many other respiratory therapists at the time. The participants of this conference recognized that many accepted respiratory therapy practices were not supported by adequate investigation: that they were based on clinical impression rather than rigorously conducted studies. The publication of these proceedings brought the predominant respiratory therapy procedure at the time, intermittent positive-pressure breathing (IPPB), under considerable scrutiny. Because evidence for benefit of IPPB was not forthcoming, this therapy has become virtually extinct in the 40 years following that conference. Reading the proceedings of the Sugarloaf Conference was instrumental in sparking my interest in evidence-based practice.
The emergence of evidence-based medicine (EBM) as a systematic distinct entity is traced to 1992, 2 with publication of the Users' Guides to the Medical Literature. 3 Today EBM has permeated all parts of healthcare practice. This paper is an extension of a paper I published from the 2003 New Horizons Symposium. 4 Respiratory care practice demands evidence for the accuracy of diagnostic tests, and for the efficacy and safety of the treatments that we apply. The traditional sources of this evidence are lacking. Experts are inadequate, lectures are ineffective, and professional journals are overwhelming. Textbooks are a useful collection of large amounts of background information, but the information is often outdated soon after publication. Our clinical assessment skills increase over time, but our knowledge tends to decrease over time. We are often too busy with our professional and personal lives to read the increasing body of research that is published weekly. The principles of EBM provide the tools to incorporate the best evidence into everyday practice.
What Is Evidence-Based Medicine?
EBM is the integration of individual clinical expertise with the best available evidence from systematic research and the patient's values and expectations. 5 The best evidence is not static, but changes when better evidence becomes available. EBM does not devalue clinical skills and clinical judgment. To the contrary, EBM medicine demands a high level of clinical skill and judgment. The practice of EBM requires us to apply the evidence to the right patient, at the right time, in the right place, at the right dose, and using the right resources.
Clinical evidence comes from real clinical research among intact patients. Bench studies and animal studies do not trump patient studies. These lower levels of evidence can be supportive of human studies, but they should not be used to invalidate the results of clinical studies.
Patient values and expectations are an important part of EBM. For example, there is a compelling body of highlevel evidence supporting the use of noninvasive ventilation (NIV) in patients with an exacerbation of COPD. Some patients, however, may prefer not to receive NIV. Another example relates to the choice of an aerosol delivery device, where a patient may prefer to use a nebulizer rather than a metered-dose inhaler. Although this may contradict the bias of the clinician, the patient's choice should be respected.
EBM is not cookbook medicine or cost-cutting medicine. The best evidence needs to be extrapolated to the patient's unique pathophysiology and values. High-level evidence is used to treat the majority of patients (the typical patient), but there are there are cases where only lowlevel evidence is available. This requires wisdom to select the best evidence when caring for the individual patient. With the implementation of EBM, costs may increase, decrease, or remain unchanged.
Hierarchy of Evidence
A hierarchy of evidence can be used to assess the strength upon which clinical decisions are made (Table 1) . 3 Clinicians should use the highest available evidence when making clinical decisions. Note that evidence always exists, but may be weak. The strongest available evidence may be an unsystematic clinical observation or a generalization from physiologic studies. Regardless of the source, there is always evidence.
Randomization is an important attribute of higher levels of evidence. Randomized controlled trials are compared to observational studies in Figure 1 . The highest level of evidence is an N of 1 randomized controlled trial (RCT). In the N of 1 RCT, patients undertake pairs of treatment periods in which they receive a target treatment in one period of each pair, and a placebo or alternative in the other. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The order of the target and control is randomized, and quantitative ratings are made for each treatment. The N of 1 RCT continues until both the patient and cli- There are some therapies for which there has not been a randomized trial, and for which one might argue that a randomized trial is either unethical or unnecessary. For example, it is unnecessary that a randomized trial be conducted to study the survival benefit of mechanical ventilation in patients with apnea, transfusion for massive blood loss, or antibiotics for bacterial pneumonia. In a tonguein-cheek paper arguing this point, Smith and Pell 17 conducted a systematic review of RCTs to determine whether parachutes are effective in preventing major trauma related to gravitational challenge. They were unable to identify any RCTs of parachute intervention and concluded that, as with many interventions intended to prevent ill health, the effectiveness of parachutes has not been subjected to rigorous evaluation by using RCTs. They go on to suggest that everyone might benefit if the most radical protagonists of EBM organized and participated in a double blind, randomized, placebo controlled, crossover trial of the parachute.
In respiratory care the evidence to support many therapies is weak. Just because a therapy is unproven does not mean that it is wrong. But it also does not mean that it is right. And just because a therapy is new does not necessarily mean that it is better.
High-level studies are prospective, randomized, blinded, placebo-controlled, concealed allocation, parallel design, and assess patient-important outcomes (Table 2) . Clinicians are often interested in physiologic outcomes, such as an improvement in arterial blood gas results. Patients, on the other hand, are more interested in outcomes such as survival. There are a number of examples in which an improvement in physiologic outcomes does not correlate with patient-important outcomes. High tidal volume (V T ) in patients with ARDS improves the arterial blood gases, but mortality is lower for small V T . 18 For patients with ARDS, inhaled nitric oxide improves P aO 2 , but not mortality. 19 Mask CPAP for acute hypoxemic respiratory failure improves P aO 2 , but not intubation rate or mortality. 20 Using the tools of EBM, metrics can be calculated such as event rate, relative risk, relative risk reduction, absolute risk reduction, number needed to treat (NNT), odds ratio (OR), and hazard ratio ( Table 3) . The confidence interval is defined as the range of values within which it is probable that the true value lies. The size of the confidence interval is determined by sample size and effect size. A larger sample size narrows the range of the confidence interval, increasing the precision of the study results and decreasing the risk of a false negative type 2 (beta) error (an effect exists but has not been detected). On the other hand, an excessively large study wastes resources, potentially places some patients at the risk of harm, increases the likelihood that a small and perhaps unimportant effect will be statistically significant, and increases the risk of a false positive type 1 (alpha) error (there appears to be an effect but there is none). The authors of high-level studies have conducted a power analysis during study design to determine the appropriate sample size.
Finding the Evidence

Asking the Question
Finding the best evidence begins with clearly articulating the question. PICO is a mnemonic used to help remember the key components of a well focused question: patient or problem, intervention, comparison, and outcomes. 3, 21 Examples of PICO questions are shown in Table 4 .
Source Literature
Primary studies supply the source evidence, but the information they contain needs critical assessment before application to clinical problems. Methods for conducting an online search to identify source literature are described in detail elsewhere. [22] [23] [24] A commonly used search engine is Google (http://www.google.com). Conducting a search using Google is a quick way to find lots of information, but the amount of information obtained can be overwhelming and involve a considerable amount of time filtering through the search results. Much of the information that is found may be irrelevant. Moreover, the validity of information may be outdated or incorrect; it is almost never subjected to peer review. Google Scholar (http://scholar.google.com) provides searching of scholarly information, such as arti- Fig. 1 . Comparison between a randomized controlled study and an observational study. With the observational study, subjects are assigned to the treatment and control groups as a matter of choice or happenstance. With the randomized controlled study, subjects are randomly assigned to the treatment and control groups. As a result, there is less bias in the randomized study.
cles, dissertations, books, abstracts, and full text from publishers. Google Scholar ranks material and links to other documents that cite an important item you have identified.
MEDLINE is the National Library of Medicine database of indexed journal citations and abstracts. PubMed (www.pubmed.gov), the online interface to MEDLINE, is easy to use but overwhelming because of the large number of articles: more than 20 million. To search PubMed, enter search terms in the query box. The Advanced search feature allows content to be limited, such as to a specific The participant of interest is unaware of whether subjects have been assigned to the experimental or control group. Subjects, clinicians, those monitoring outcomes, assessors of outcomes, data analysts, and those writing the paper can all be blinded. Placebo
Interventions without biologically active attributes.
Concealment
Randomization is concealed if the person who is making the decision about enrolling a patient is unaware of whether the next patient enrolled will be entered in the treatment or control group. Parallel design With a parallel study design, subjects are randomly assigned to the treatment or control group, an intervention is applied, and the outcome is identified for each subject. This is different than a crossover study, in which subjects receive both the treatment and control intervention. Event rate Proportion of subjects in a group in whom an event is observed. Control event rate and experimental event rate refer to this in control and experimental groups of subjects, respectively. Relative risk Ratio of the risk of an event among an experimental group to the risk among the control group. A relative risk Ͻ 1 means benefit, a relative risk Ͼ 1 means harm, and a relative risk ϭ 1 means the intervention has no effect.
Relative risk reduction
Estimate of the proportion of baseline risk that is removed by the therapy. Absolute risk reduction Difference in the absolute risk (percentage or proportion of subjects with an outcome) in the exposed (experimental event rate) versus the unexposed (control event rate). Number needed to treat Number of subjects who need to be treated to prevent one bad outcome.
Odds ratio
Ratio of the odds of an event in an exposed group to the odds of the same event in a group that is not exposed.
Hazard ratio
Ratio of the hazard rates corresponding to the conditions described by 2 levels of an explanatory variable; a measure of how often a particular event happens in one group compared to how often it happens in another group, over time. 
com) is a large
European database that is similar to MEDLINE in scope and content, with strengths in drugs and allied health disciplines. Up to 70% of citations in EMBASE are not included in MEDLINE. Ovid (www.ovid.com) provides medical information services to individuals in medical schools, hospitals, and academic institutions. Ovid provides access to a large selection of databases, including MEDLINE, CINAHL, and the other bibliographic databases. Most journals, including RESPIRATORY CARE, provide searching of journal contents by keyword or author directly from their home pages.
Many clinicians find it useful to scan journal contents monthly for new articles relevant to their practice. This is easily accomplished by subscribing to the e-mail alerts provided free of charge by journals. Read by QxMD (http:// www.qxmd.com) is an application for mobile devices that provides a single place to screen papers and read full text. It allows the user to follow specific journals and collections. It is also useful to use a citation manager to organize full text articles. My favorite application to accomplish this is Papers (http://www.papersapp.com), but similar features are available from EndNote, Reference Manager, RefWorks, and others. Citation manager software allows full text to be imported, and also allows one to conduct the online search from within the program and download directly to the citation manager.
Systematic Reviews
Narrative state-of-the-art reviews, such as those published in RESPIRATORY CARE from Journal Conferences and the New Horizons Symposia, are popular among readers. However, they are often limited by incomplete searches of the literature, intentional or unintentional bias by the authors, and failure to account for the quality of individual publications. Narrative reviews typically fail to effectively deal with studies having conflicting results, as they are written by experts who rely on their own experience and expertise rather than on a critical assessment of all available evidence. 25 A systematic review is a summary of the literature that uses explicit methods, is based on a thorough literature search, performs a critical appraisal of individual studies, and uses statistical techniques to combine valid studies (meta-analysis). 25 In a systematic review the primary evidence is rigorously identified and appraised. Unlike the traditional narrative review, a systematic review uses explicit methods. A systematic review details the methods by which papers were identified in the literature, it uses predetermined criteria for selection of papers to be included in the review, and it critically assesses the evidence and bases the review on the strength of that evidence. Narrative and systematic reviews are compared in Table 5 .
Several sources can be searched for systematic reviews. PubMed can be searched using "systematic reviews" as article type. Ovid can be searched using the specific databases "EBM Reviews." The Cochrane Database (www. cochrane.org) is a rich source of systematic reviews, including many related to respiratory care. Systematic reviews and clinical practice guidelines may be outdated and should be supplemented by recent RCTs published after the publication date of the review or guideline.
Meta-Analysis
Individual studies should be placed in the context of the totality of evidence. 26 The following reasons have been proposed to shift the collective focus from single studies to the accumulating body of evidence.
• Calibrate confidence in the estimates based on the consistency with other studies. Replication is a key step in science.
• Avoid premature closure about the magnitude of the effect before the estimate has moderated through repeated and independent evaluation. The most favorable result in support of a specific association is more likely to appear earlier than the least favorable one.
• Calibrate confidence in the estimates based on the true magnitude of precision. When results are inconsistent, the relative precision around the estimate of effect from a single study will overestimate the precision that the study contributes to the accumulating evidence.
• Improve the usefulness of results to clinical decision makers. Studies often adopt design features that help yield seemingly definitive findings. These features include using composite end points, surrogate end points, unfair comparisons, and selecting patients at high risk of the outcome.
• Prevent premature dismissal of a potentially effective intervention owing to concerns about nonsignificant results.
Meta-analysis is a statistical analysis that combines the results of several independent studies. 25 A meta-analysis of RCTs is a higher level of evidence than a single RCT. A meta-analysis uses statistical methods to combine the results of several studies into a single pooled metric. Since it is based on a literature review, the meta-analysis is observational rather than experimental in nature.
The person conducting the meta-analysis has limited control over the availability of studies or the information reported in the individual studies. The studies included in the meta-analysis should be comparable, but the degree of comparability is subjective and determined by the person conducting the meta-analysis. Included studies should be identified from a comprehensive review of the literature, and unpublished data should be included to reduce the risk of publication bias. Tests for heterogeneity can be reported in the results of a meta-analysis. A common test of heterogeneity is the I 2 , which describes the percentage of the variability in effect estimates that is due to underlying differences in effect rather than chance. An I 2 Ͻ 20% represents minimal heterogeneity, 20 -50% raises concern, and Ͼ 50% represents substantial heterogeneity. Betweenstudy variability should be examined by looking for differences in patients, interventions, outcome measurement, and methodology. 3 In a meta-analysis, if the odds ratio (OR), risk ratio, or relative risk exceeds 1, the likelihood of the outcome is greater in the treatment group. On the other hand, if it is below 1, the outcome is less likely in the treatment group. If the value is close to 1, the outcomes in the treatment and control groups are more similar. If the confidence interval overlaps 1, the results are not significantly different from one another. A wider confidence interval indicates a less precise treatment effect, which is often due to smaller sample size.
The results of a meta-analysis are displayed as a forest plot. 25 The outcome is placed on the x-axis and the vertical line at 1.0 represents the no-effect line. Confidence intervals that cross this vertical line indicate that the study groups have equal risk of the outcome of interest. The square boxes are the point estimates for each study, and often (but not always) are presented as different-sized boxes, which correspond to the weight given to the study. A larger box reflects a higher weight assigned to that study. The cumulative treatment effect is represented by the diamond symbol at the bottom of the diagram. The center of the diamond represents the point estimate of the combined result, and the width of the diamond represents the 95% confidence interval of the point estimate.
Clinical Practice Guidelines
Evidence-based clinical practice guidelines ask relevant questions, systematically search the literature using explicit methodology, grade the level of the evidence, make recommendations, and grade the recommendations based upon the strength of the evidence. 27 The recommendations of the evidence-based guidelines are supported by evidence, and the level of evidence is unambiguous and defensible. Clinical practice guidelines are often accompanied by systematic reviews and meta-analysis. They are often supported by professional organizations, including the American Association for Respiratory Care. 28 The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach is increasingly used to grade the quality of supporting evidence and the strength of recommendations in healthcare. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] The GRADE system provides a detailed stepwise process that defines the quality of the available evidence in the development of recommendations ( Table 6 ). The value of GRADE is not that it eliminates judgments or disagreements about evidence and recommendations, but rather that it makes them transparent.
The public should trust clinical 39 practice guidelines only if the recommendations accurately reflect the underlying evidence about benefits and harms to individual patients. 39 This requires a rigorous process for assembling, evaluating, and summarizing the evidence. Often this is the result of a rigorous systematic review. A second requirement is the process used to decide the recommended strategies that best offer a favorable balance of harms and benefits. The Institute of Medicine developed the Appraisal of Guidelines for Research and Evaluation (AGREE) system to set of standards for rating the quality of the process of guideline development.
Therapy That Evidence Supports Noninvasive Ventilation
In a Cochrane review of 14 studies, Ram et al 40 Clinical practice guidelines were prepared by an 18-member guidelines panel as an initiative of the Canadian Critical Care Trials Group/Canadian Critical Care Society Noninvasive Ventilation Guidelines Group. 42 Guidelines were graded with the GRADE approach. The final review included 146 RCTs. Guidelines were prepared on COPD exacerbation, asthma exacerbation, cardiogenic pulmonary edema, acute lung injury, chest trauma, immunosuppression in conjunction with acute respiratory distress or failure, bronchoscopy in patients with hypoxemia, adjunct to early liberation from mechanical ventilation, prevention of acute respiratory failure after low-risk surgery, prevention of acute respiratory, failure after high-risk surgery, treatment of acute respiratory failure after surgery, interface, and preferred mode for NIV. The following key points summarize this clinical practice guideline:
• NIV should be the first option for ventilatory support for patients with either a severe exacerbation of COPD or cardiogenic pulmonary edema.
• CPAP delivered by mask appears to be just as effective as NIV for patients with cardiogenic pulmonary edema.
• Patients with acute respiratory distress or hypoxemia, either in the postoperative setting or in the presence of immunosuppression, can be considered for a trial of NIV.
• Patients with COPD can be considered for a trial of early extubation to NIV.
A comparative effectiveness review commissioned by the Agency for Healthcare Research and Quality evaluated the evidence for NIV versus other typical treatments for acute respiratory failure. 43 The review includes 44 studies (4,122 subjects) that compared NIV to supportive care, 5 (405 subjects) compared NIV to invasive ventilation, 12 (1,520 subjects) compared NIV to CPAP, and 12 (1,463 
Lung-Protective Ventilation
In the seminal ARDS Network study, 18 861 patients with ARDS were randomly assigned to mechanical ventilation with a V T of 12 mL/kg or 6 mL/kg, based on ideal (predicted) body weight and not actual body weight. Mortality for the control group (12 mL/kg V T ) was 39.8%, and mortality for the experimental group (6 mL/kg V T ) was 31%. The relative risk of mortality was lower for the 6 mL/kg group (0.79), with a relative risk reduction of 0.21 compared to the 12 mL/kg group. There was an absolute risk reduction for mortality of 8.8%, resulting in an NNT of 11 patients.
In a multicenter prospective cohort study, Needham et al 44 also found that higher survival is associated with lung-protective ventilation. They enrolled 485 subjects for 6,240 eligible ventilator settings, of which 41% adhered to lung-protective ventilation. After adjusting for the duration of ventilation and other relevant covariates, each additional ventilator setting adherent to lung-protective ventilation was associated with a 3% decrease in the risk of mortality over 2 years (hazard ratio 0.97, 95% CI 0.95-0.99, P ϭ .002). Compared with no adherence, the estimated absolute risk reduction in 2-year mortality for a patient with 50% adherence to lung-protective ventilation was 4.0% (P ϭ .01), and with 100% adherence was 7.8% (P ϭ .01). Average V T showed an independent linear relation with 2-year survival, with an 18% relative increase in the risk of mortality for each 1 mL/kg predicted body weight increase in average V T over the duration of mechanical ventilation.
A meta-analysis by Serpa Neto 45 suggests that use of lower V T also benefits patients who do not have ARDS. Their meta-analysis included 20 articles (2,822 subjects). Their results show a decrease in lung injury development (risk ratio 0.33, 95% CI 0.23-0.47, NNT 11) and mortality (risk ratio 0.64, 95% CI 0.46 -0.89, NNT 23) in patients receiving ventilation with lower V T . The results of lung injury development were similar when stratified by the type of study (randomized vs nonrandomized), and were significant only in randomized trials for pulmonary infection and only in nonrandomized trials for mortality. The meta-analysis also showed, in protective ventilation groups, a lower incidence of pulmonary infection (risk ratio 0.45, 95% CI 0.22-0.92, NNT 26), lower hospital stay, higher P aCO 2 , lower pH, and similar P aO 2 /F IO 2 .
Ventilator Discontinuation Protocols
More than 10 years ago, evidence-based guidelines for weaning and discontinuing ventilatory support were published. 46 One of the recommendations in these guidelines was that discontinuation protocols designed for non-physician healthcare professionals should be developed and implemented. More recently, a Cochrane systematic review and meta-analysis addressed the use of weaning protocols for reducing duration of mechanical ventilation in critically ill adult patients. 47 Eleven trials that included 1,971 patients were included. Compared with usual care, the geometric mean duration of mechanical ventilation in the weaning protocol group was reduced by 25% (95% CI 9 -39%, P ϭ .006, 10 trials), the duration of weaning was reduced by 78% (95% CI 31-93%, P ϭ .009, 6 trials), and stay in the ICU by 10% (95% CI 2-19%, P ϭ .02, 8 trials). Available evidence supports that the use of ventilator discontinuation protocols improves patient outcomes.
Therapy That Evidence Does Not Support Weaning Parameters
In the past, many potential predictors of successful or unsuccessful liberation from mechanical ventilation have been proposed. Meade et al 48 identified 65 observational studies of weaning predictors. For spontaneous breathing trials (SBT) the power of a positive test result for both breathing frequency and rapid shallow breathing index (RSBI) were limited (highest likelihood ratio 2.23), while the power of a negative test result was substantial (likelihood ratio 0.09 -0.23). Summary data suggest a similar predictive power for breathing frequency and RSBI. In the prediction of successful extubation, a breathing frequency Ͻ 38 breaths/min (sensitivity 88%, specificity 47%) and a RSBI Ͻ 105 breaths/min/L (sensitivity 65-96%, specificity 0 -73%) are the most promising. A breathing frequency Ͼ 38 breaths/min and a RSBI of Ͼ 100 breaths/min/L reduce the probability of successful extubation. Judging by areas under the receiver operator curve for all variables, none of these variables demonstrate more than modest accuracy in predicting weaning outcome.
Tanios and colleagues 49 conducted a multicenter randomized blinded controlled trial in 304 subjects to determine the effect of including RSBI in a weaning protocol. In one group the RSBI was measured but not used in the decision to wean, but in the other group RSBI was measured and used. Subjects passing the screen received a 2-hour SBT, and those who passed the SBT were eligible for extubation. The median duration for weaning time was significantly shorter in the group where RSBI was not used (2.0 d vs 3.0 d, P ϭ .04). There was no difference with regard to the extubation failure, in-hospital mortality rate, tracheostomy, or unplanned extubation. The results of this study suggest that use of RSBI might result in prolonged weaning time. These authors recommend that RSBI should not be used routinely in weaning decision-making.
A properly monitored SBT is very safe and effectively identifies patients ready for liberation from mechanical ventilation. 46 Given that weaning parameters are not highly predictive of readiness for an SBT or readiness for extubation, weaning parameters can be omitted from practice, with emphasis placed on performance of an SBT. Common criteria for discontinuation of an SBT include tachypnea, desaturation, tachycardia or bradycardia, hypertension or hypotension, agitation, diaphoresis, or anxiety. These are identified at the bedside by a clinician, such as a respiratory therapist, without the need for weaning parameters.
Albuterol for ARDS
In the past it was believed that inhaled ␤ 2 agonists were benign, and might help, in all mechanically ventilated patients. In many hospitals they are commonly administered to all mechanically ventilated patients. Moreover, there was some experimental and clinical evidence that ␤ 2 agonists accelerate resolution of pulmonary edema. Thus, the ARDS Network conducted a multicenter randomized, placebo-controlled clinical trial in which 282 mechanically ventilated subjects with ARDS were randomized to receive aerosolized albuterol or placebo every 4 hours for up to 10 days. 50 Ventilator-free days were not significantly different between the albuterol and placebo groups (means of 14.4 d and 16.6 d, respectively). Mortality before hospital discharge was not significantly different between the albuterol and placebo groups (23.0% and 17.7%, respectively). In another multicenter placebo-controlled trial, 51 328 mechanically ventilated subjects with ARDS onset were randomly assigned to receive either intravenous salbutamol or placebo for up to 7 days. Salbutamol increased 28-day mortality (34% vs 23%, risk ratio 1.47, 95% CI 1.03-2.08). These data suggest that administration of ␤ 2 agonists to mechanically ventilated patients with ARDS is unlikely to be beneficial, and could worsen outcomes. Routine use of ␤ 2 -agonist therapy in mechanically ventilated patients with ARDS cannot be recommended.
High Frequency Oscillatory Ventilation for Adults
High frequency oscillatory ventilation (HFOV) theoretically meets the goals of a strategy of lung-protective ventilation, with small V T lung recruitment. The use of HFOV in adults with ARDS has been controversial. 52 Sud et al 53 conducted a meta-analysis of 8 RCTs. In subjects randomized to HFOV, mortality was significantly reduced (risk ratio 0.77, 95% CI 0.61-0.98, P ϭ .03), and treatment failure (refractory hypoxemia, hypercapnia, hypotension, or barotrauma) resulting in discontinuation of assigned therapy was less likely (risk ratio 0.67, 95% CI 0.46 -0.99, P ϭ .04). There are several criticisms, however, of this meta-analysis. First, it combined studies of adults and children. Second, several of the studies were published in abstract only. Recently, 2 large RCTs of the use of HFOV in adults were published. 54, 55 One of these reported no difference between conventional ventilation and HFOV, 55 but the other reported worse outcomes for HFOV. 54 An updated meta-analysis of 4 randomized RCTs [54] [55] [56] [57] in adults, comparing HFOV and conventional ventilation shows no difference in mortality (Fig. 2) , although the heterogeneity is large (I 2 ϭ 69%). The accumulated evidence does not support the use of HFOV in adults with ARDS.
Therapy With Equivocal Evidence
Airway Clearance
Clearance of airway secretions is a primary therapy for patients with cystic fibrosis. Over the years, a variety of airway clearance therapies (ACTs) have been developed. The Cystic Fibrosis Foundation established a committee to Fig. 2 . A meta-analysis of mortality in 4 randomized controlled trials of high frequency oscillatory ventilation (HFOV) versus conventional ventilation. There is no difference in mortality, and a tendency toward lower mortality in the subjects receiving conventional ventilation. M-H Mantel-Haenszel test. (Data from references 53-56.) examine the clinical evidence for each therapy and provide guidance for their use. 58 A systematic review identified 7 unique reviews and 13 additional controlled trials that addressed 1 or more of the comparisons of interest and were deemed eligible for inclusion. Recommendations for use of the ACTs were made, balancing the quality of evidence and the potential harms and benefits. The committee determined that, although there is a paucity of controlled trials that assess the long-term effects of ACTs, the evidence of quality overall for their use in cystic fibrosis is fair and the benefit is moderate. The committee recommends that airway clearance should be performed on a regular basis in all patients with cystic fibrosis. However, no ACT was found to be superior to the others. Therefore, it was recommended that the prescription of ACTs should be individualized.
Ides and colleagues 59 conducted a systematic review of ACT for patients with COPD. They found that studies that provide solid evidence of the effectiveness of different ACTs in patients with COPD are scarce. The available evidence indicates that active breathing techniques, such as active cycle of breathing techniques, autogenic drainage, and forced expiration, can be effective in the treatment of COPD. However, the evidence for passive techniques such as postural drainage and percussion is low. Other techniques, such as intrapulmonary percussive ventilation, positive expiratory pressure, and NIV, have little evidence because of the small number of studies. Little evidence was also found for the combined use of active techniques and techniques such as oscillating positive expiratory pressure, postural drainage, and vibration in COPD.
There is a dearth of high-level evidence related to ACTs. Studies in this field are hampered by small sample sizes, crossover designs, assessment of a single treatment session, less than careful attention to technique, surrogate outcome measures, lack of blinding, and statistical concerns. I have suggested the following hierarchy of questions that might be asked when considering ACT for a patient. 10 • Is there a pathophysiologic rationale for use of the therapy? Is the patient experiencing difficulty in clearing of secretions? Are retained secretions affecting lung function in an important way, such as gas exchange or lung mechanics? Note that the production of large amounts of sputum does not necessarily mean that the patient is experiencing difficulty clearing sputum.
• What is the potential for adverse effects from the therapy? Which therapy is most likely to provide the greatest benefit with the least harm?
• What is the cost of the equipment for this therapy? The cost of the device may not be covered by insurance, resulting in considerable out-of-pocket expense for the patient or the hospital.
• What are the preferences of the patient? Lacking evidence that any technique is superior to another, patient preference is an important consideration.
When a clinical decision is made to try a secretion clearance technique, an N of 1 trial can be conducted.
Aerosol Device
There are advantages and disadvantages associated with each aerosol device category (nebulizer, metered-dose inhaler, dry powder inhaler). But the variety of devices has resulted in a confusing number of choices for clinicians who are selecting an aerosol delivery device for an individual patient. Dolovich and colleagues 60 prepared evidence-based guidelines for the selection of an appropriate aerosol delivery device in specific clinical settings. A systematic review of pertinent RCTs was undertaken. Of the 131 studies that met the eligibility criteria, only 59 studies, primarily those that tested ␤ 2 agonists, had useable data. None of the pooled meta-analyses showed a significant difference between devices in any efficacy outcome in any patient group for each of the clinical settings that was investigated. The authors concluded that aerosol delivery devices used for the delivery of bronchodilators and steroids can be equally efficacious. When selecting an aerosol delivery device for patients with asthma and COPD, they suggest that the following should be considered:
• Device/drug availability The authors also point out the crucial importance of patient instruction in the proper use of the device.
PEEP for ARDS
A matter of controversy is how to set PEEP for the patient with ARDS. To date, 6 clinical trials have assessed the application of lower versus higher PEEP in patients with ARDS. 61, 62 Only 2 reported a significant mortality reduction with higher PEEP In these studies, however, 2 interventions were applied: a higher PEEP was combined with a lower V T . Thus, it is unknown whether the mortality benefit was related to the higher PEEP, lower V T , or a combined effect. There are 5 meta-analyses published on the topic of higher versus lower PEEP in patients with ARDS. Of these, 4 found no effect on mortality from higher PEEP, compared with moderate PEEP.
The meta-analysis by Briel et al 63 is unique in that data from 2,299 individual patients in 3 trials were analyzed, using uniform outcome definitions. The mortality rate was 33% for patients assigned to treatment with higher PEEP, and 35% for patients assigned to lower PEEP (adjusted relative risk 0.94, 95% CI 0.86 -1.04, P ϭ .25). However, in patients with moderate to severe ARDS the mortality was 34% in the higher-PEEP group and 39% in the lower-PEEP group (adjusted relative risk 0.90, 95% CI 0.81-1.00, P ϭ .049). In patients with mild ARDS the mortality was 27% in the higher-PEEP group and 19% in the lower-PEEP group (adjusted relative risk 1.37, 95% CI 0.98 -1.92, P ϭ .07). The results of this meta-analysis suggest that treatment with higher PEEP was associated with improved survival among the subgroup of patients with moderate to severe ARDS. But there was a trend toward worse outcomes with higher PEEP in the subgroup with mild ARDS. There are many techniques that can be used to select PEEP, but evidence is lacking for superiority of one approach, compared to the others.
Why Isn't the Best Evidence Implemented
Into Practice?
The tenets of EBM are not universally accepted. A variety of reasons have been given to support a practice not consistent with EBM (Table 7) . Some clinicians do not accept a hierarchy of evidence, or grading of the evidence, arguing instead that experiential evidence and evidence from physiologic trials are equally important, or perhaps even more important, than evidence by well done, prospective randomized trials in humans. [64] [65] [66] Clinical wisdom is required to determine whether or not the evidence is valid and how the evidence is best applied to the care of an individual patient. It is often pointed out that high-level evidence does not exist for many respiratory care practices. However, that is no excuse for not implementing high-level evidence when it is available. EBM does not discredit the value of observational studies, physiologic studies, and clinical experience. Such evidence is important to assess mechanisms of disease and to establish proof of principle. However, lower levels of evidence should impact clinical practice less than the results of a well done RCT.
It has been reported that about 30 -40% of patients do not receive care according to best evidence. The ARDS Network study 18 is a case in point. Despite the strong finding that mortality is lower with a V T of 6 mL/kg, compared to 12 mL/kg, the practice of using lower V T in patients with ARDS remains under-utilized. In 13 ICUs at 4 hospitals in Baltimore, Maryland, only 41% of eligible ventilator settings collected from 2004 to 2007 were adherent to lung-protective ventilation, and 37% of patients never received lung-protective ventilation. Another case in point is NIV, where it has been reported in several studies that this therapy is under-utilized. [67] [68] [69] In 1 study of patients admitted to ICUs with a diagnosis of either COPD or congestive heart failure exacerbation, only a third had a trial of NIV. 70 
Summary
EBM has permeated all parts of healthcare practice, including respiratory care. The principles of EBM provide us the tools to incorporate the best evidence into our everyday practice. Although all tenets of EBM are not universally accepted, the principles of EBM nonetheless provide a valuable approach to improve respiratory care practice. Table 7 . Common Reasons Why Clinicians Do Not Practice Evidence-Based Medicine They do not recognize the evidence (laziness) They do not read the literature They do not attend conferences They do not talk to their colleagues They do not believe the evidence (ignorance) They do not believe the right study was done (eg, wrong dose) The study is not consistent with lower levels of evidence (eg, animal studies) They believe that incorporating the evidence into practice is someone else's job (blaming) The system prevents incorporating the latest evidence There is not enough time The right resources are not available There is not hospital policy supporting the practice change They do not think the evidence applies to their practice (stubbornness) Their patients are sicker Their patients are older Their patients have always done fine with their "expert" treatment (From reference 4.)
